Inozyme Pharma
Clinical trials sponsored by Inozyme Pharma, explained in plain language.
-
New drug offers hope for babies with rare, deadly artery disease
Disease control Recruiting nowThis study tests a new medicine called INZ-701 in babies up to 1 year old who have a rare genetic condition called ENPP1 deficiency. The condition causes severe hardening of the arteries and rickets. The goal is to see if the medicine can raise a key substance in the blood, impro…
Phase: PHASE3 • Sponsor: Inozyme Pharma • Aim: Disease control
Last updated May 26, 2026 12:01 UTC
-
New hope for babies with rare calcification diseases: drug trial launches
Disease control Recruiting nowThis early-stage study tests a new medicine called INZ-701 in up to 16 infants (up to 1 year old) who have rare genetic conditions that cause dangerous calcium buildup in blood vessels and bones. The main goal is to check if the drug is safe and how it affects the body, especiall…
Phase: PHASE1 • Sponsor: Inozyme Pharma • Aim: Disease control
Last updated May 26, 2026 11:59 UTC
-
New registry aims to unlock secrets of rare genetic diseases
Knowledge-focused Recruiting nowThis study is a registry that collects information from people with two rare genetic conditions: ENPP1 deficiency and infantile-onset ABCC6 deficiency. Researchers will gather data from routine doctor visits and patient questionnaires to understand how these diseases progress and…
Sponsor: Inozyme Pharma • Aim: Knowledge-focused
Last updated May 26, 2026 12:05 UTC